US4898733A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Layered, compression molded device for the sustained release of a beneficial agent
Assignee: International Minerals and Chemical Corp
•
Filing: 1985-11-04
•
Granted: 1990-02-06
•
Expires: 2005-11-04
Abstract
Abstract A device for the continuous administration of a beneficial agent to a living being at a substantially steady rate which comprises: (a) a body fluid-contacting layer which comprises a dispersion of an agent which is substantially soluble in the body fluid and a solid matrix material, said matrix material comprising a polymer which is substantially insoluble in said body fluid, and (b) a non-body fluid-contacting layer which comprises said beneficial agent, wherein said body fluid-contacting layer is compression molded to said non-body fluid contacting layer.
Inventors
- 👤 Randolph B. DePrince
- 👤 Ravi Viswanathan
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 20:09
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0087; A61K9/0092; A61M; A61M31/00; A61M31/002
Claims Analysis
Total Claims: 25
Claim 1
Independent Claim
97 words
A partially coated device for the continuous administration of a beneficial agent in the body of a living being at a substantially steady rate which comprises: (a) a body fluid-contacting layer which comprises a dispersion of an agent which is substantially soluble in body fluid and a solid matrix material, said matrix material comprising a polymer which is substantially insoluble in said body fluid, and (b) a non-body fluid-contacting layer which comprises a reservoir of said beneficial agent, wherein said body fluid-contacting layer is compression molded to said non-body fluid-contacting layer to form a tablet or pellet.
Claim 2
Dependent Claim
97 words
A partially coated device for the continuous administration of a beneficial agent in the body of a living being at a substantially steady rate which comprises: (a) a body fluid-contacting layer which comprises a dispersion of an agent which is substantially soluble in body fluid and a solid matrix material, said matrix material comprising a polymer which is substantially insoluble in said body fluid, and (b) a non-body fluid-contacting layer which comprises a reservoir of said beneficial agent, wherein said body fluid-contacting layer is compression molded to said non-body fluid-contacting layer to form a tablet or pellet.
Claim 3
Dependent Claim
31 words
A device in accordance with claim 1, which comprises more than one body fluid-contacting layer, wherein each of said body fluid contacting layers is compression molded to said non-body fluid-contacting layer.
Claim 4
Dependent Claim
24 words
The device of claim 1 or 2 wherein said matrix material is a comminuted polymer which is biocompatible with body tissue and body fluids.
Claim 5
Dependent Claim
69 words
The device of claim 3 wherein said polymer is selected from the group consisting of acyl substituted cellulose acetates and alkyl derivatives thereof, partially and completely hydrolyzed alkylene-vinyl acetate copolymers unplasticized polyvinyl chloride, cross-linked homo- and copolymers of polyvinyl acetate, cross-linked polyesters of acrylic and methacrylate, polyvinyl alkyl ethers, polyvinyl fluoride, silicone, polycarbonate, polyurethane, polyamide, polysulphones, styrene acrylonitrile copolymers, cross-linked poly(ethylene oxide) poly(alkylenes) poly(vinyl imidazole), poly(esters) and chlorosulphonated polyolefins.
Claim 6
Dependent Claim
30 words
The device of claim 4, wherein said polymer is an alkylene-vinyl acetate copolymer selected from the group consisting of ethylene vinyl acetate, ethylene vinyl methylacetate, ethylene-vinyl ethyl-acetate and ethylene-vinyl propylacetate.
Claim 7
Dependent Claim
21 words
The device of claim 1 or 2, wherein said beneficial agent comprises a drug, vitamin, nutritional supplement or biologically active protein.
Claim 8
Dependent Claim
34 words
The device of claim 6, wherein said beneficial agent is a drug selected from the group consisting of hypnotics, sedatives, tranquilizers, anti-convulsants, muscle relaxants, analgesics, anti-inflammatory agents, local anesthetics, antimicrobials, steroids, sympathomimetrics and diuretics.
Claim 9
Dependent Claim
13 words
The device of claim 6, wherein said agent is a biologically active protein.
Claim 10
Dependent Claim
17 words
The device of claim 1 or 2, wherein said non-body fluid-contacting layer additionally comprises a binder material.
Claim 11
Dependent Claim
29 words
The device of claim 9, wherein said non-body fluid contacting layer comprises a maximum of about 20 parts by weight binder to about 80 parts by weight beneficial agent.
Claim 12
Dependent Claim
26 words
The device of claim 10, wherein said non-body fluid contacting layer comprises about 10 parts by weight binder and about 90 parts by weight beneficial agent.
Claim 13
Dependent Claim
32 words
The device of claim 9 wherein said binder is selected from the group consisting of sodium bentonite, ethyl cellulose, stearic acid, calcium stearate, adipic acid, fumaric acid, polyethylene glycol and cellulose acetate.
Claim 14
Dependent Claim
12 words
The device of claim 9, wherein said binder comprises a polymeric material.
Claim 15
Dependent Claim
38 words
The device of claim 1 or 2, wherein said substantially body fluid-soluble agent is selected from the group consisting of sodium chloride, insulin and other water-soluble carbohydrates, lactose and other reducing sugars and sucrose and other non-reducing sugars.
Claim 16
Dependent Claim
10 words
The device of claim 14, wherein said agent is lactose.
Claim 17
Dependent Claim
10 words
The device of claim 14, wherein said agent is sucrose.
Claim 18
Dependent Claim
24 words
The device of claim 1 or 2, wherein said body fluid-contacting layer comprises a dispersion of beneficial agent and a solid polymeric matrix material.
Claim 19
Dependent Claim
37 words
The device of claim 1 or 2, wherein said body fluid-contacting layer comprises about 30 to about 70 parts by weight of said substantially body fluid-soluble agent and about 70 to about 30 parts by weight polymer.
Claim 20
Dependent Claim
30 words
The device of claim 18, wherein said body fluid-contacting layer comprises about 40 to about 60 parts by weight agent and about 60 to about 40 parts by weight polymer.
Claim 21
Dependent Claim
54 words
The device of claim 1 or 2, wherein after said layers have been compression molded into a tablet, said tablet is partially coated with a material substantially impermeable to said beneficial agent and said body fluid and substantially insoluble in said body fluid such that said non-body fluid-contacting layer of said tablet is coated.
Claim 22
Dependent Claim
44 words
The device of claim 1 or 2, wherein after said layers have been compression molded, the non-body fluid-contacting layer of said device is covered with a material essentially impermeable to said beneficial agent and said body fluid and essentially insoluble in said body fluid.
Claim 23
Dependent Claim
40 words
A method for the continuous administration of a beneficial agent to a living being at a substantially constant rate for a prolonged period time which comprises implanting the device of claim 1 or 2 into tissues of said living being.
Claim 24
Dependent Claim
41 words
A method for the continuous of a beneficial agent to a living being a substantially constant rate for a prolonged period of time which comprises inserting the device of claim 1 or 2 into a body cavity in the living being.
Claim 25
Dependent Claim
42 words
A method for the continuous administration of a beneficial agent to a living being at a substantially constant rate for a prolonged period of time which comprises the oral ingestion of the device of claim 1 or 2 by said living being.
References Cited (Backward Citations)
US3317394A
Cited
US2951792A
Cited
US3279996A
Cited
US3362880A
Cited
US3832252A
Cited
CA942667A
Cited
US3965255A
Cited
US3923939A
Cited
US4289795A
Cited
US4341759A
Cited
US4220152A
Cited
US4578264A
Cited
US4352883A
Cited
GB2058565A
Cited
US4298003A
Cited
US4326525A
Cited
GB2123289A
Cited
US4576604A
Cited
US4666702A
Cited
US4681755A
Cited
US4629620A
Cited
US4610870A
Cited
US4609374A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-02-05 | 1993-08-07 | 1994-02-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-02-05 | 1997-08-07 | 1998-02-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-02-05 | 2001-08-07 | 2002-02-06 | $7700.00 | Window Closed / Lapsed |